![DyneLogo_FINAL_RGB v2.png](https://www.bioindustry.org/static/6d1315b6-12fe-485f-a8b59788c3e43415/jobdetailscompanylogo_dd64811c02712599828cc4c462858531_4a7c7e45a350/DyneLogoFINALRGB-v2.png)
Dyne Therapeutics
Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.